National Bank of Canada FI Cuts Stake in Pfizer Inc. $PFE

National Bank of Canada FI lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,804,317 shares of the biopharmaceutical company’s stock after selling 3,754,957 shares during the quarter. National Bank of Canada FI’s holdings in Pfizer were worth $122,417,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in PFE. Laird Norton Wetherby Wealth Management LLC boosted its position in shares of Pfizer by 12.6% during the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 97,858 shares of the biopharmaceutical company’s stock worth $2,493,000 after acquiring an additional 10,917 shares during the last quarter. Laraway Financial Advisors Inc increased its holdings in Pfizer by 6.0% in the 3rd quarter. Laraway Financial Advisors Inc now owns 9,759 shares of the biopharmaceutical company’s stock valued at $249,000 after acquiring an additional 550 shares during the last quarter. Larson Financial Group LLC increased its holdings in Pfizer by 4.7% in the 3rd quarter. Larson Financial Group LLC now owns 131,407 shares of the biopharmaceutical company’s stock valued at $3,348,000 after acquiring an additional 5,945 shares during the last quarter. Lido Advisors LLC lifted its stake in Pfizer by 59.8% in the 3rd quarter. Lido Advisors LLC now owns 442,916 shares of the biopharmaceutical company’s stock worth $11,286,000 after purchasing an additional 165,753 shares in the last quarter. Finally, Jain Global LLC boosted its holdings in shares of Pfizer by 32.3% during the 3rd quarter. Jain Global LLC now owns 402,600 shares of the biopharmaceutical company’s stock valued at $10,258,000 after purchasing an additional 98,303 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.05.

Pfizer Stock Up 0.1%

Shares of NYSE:PFE opened at $26.61 on Tuesday. The firm has a market capitalization of $151.28 billion, a PE ratio of 19.56 and a beta of 0.47. The business has a 50 day simple moving average of $26.53 and a two-hundred day simple moving average of $25.54. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.